FDA Warns Against Unlawful Sale of Weight-Loss Drugs
Reuters
July 2, 2024
The U.S. Food and Drug Administration announced on Tuesday that it had issued a warning to the website ozempen.com for unlawfully selling versions of Novo Nordisk's weight-loss drugs.
Demand for Novo Nordisk's Ozempic, Eli Lilly's Mounjaro, and other GLP-1 drugs that promote weight loss has surged, outpacing supply and fueling a growing global market for counterfeit versions.
The health regulator stated that the website was offering unapproved versions of the obesity and diabetes drugs Ozempic and Wegovy.
"These products are only available pursuant to a prescription from a licensed practitioner," the FDA emphasized.
Last month, the World Health Organization issued warnings about counterfeit drugs claiming to contain the active ingredients found in Ozempic and Wegovy.
Eli Lilly and Novo Nordisk have sued several entities to stop the sale of products falsely claiming to contain the active ingredients tirzepatide and semaglutide, which are used in their popular diabetes and weight-loss drugs.